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A prospective, randomized therapeutic trial for schistosomal specific
nephropathy. In this work 26 patients with schistosomal specific
nephropathy were randomly distributed among three groups. Group I
cases were given anti-schistosomal drugs (oxamniquine and praziquan-
tel), group II cases were given anti-schistosomal drugs plus pred-
nisolone, and group III cases were given anti-schistosomal drugs plus
cyclosporine. The schistosomal specificity of kidney lesions was as-
sessed by detecting the schistosomal specific antigens (CAA and CCA)
and antibodies deposited in the renal glomeruli of these patients.
Patients who had another etiologic cause which may explain their
kidney disease were not admitted to this study. After initiation of the
treatment, patients were followed up every other week in the out-
patient clinic for 12 months. Follow-up showed complete remission of
proteinuria in two cases in group II (duration of remission was 4 and 8
months) and in one case in group III (duration of remission was 6
months) but in none in group I. Partial remission was observed in one
case in group I, in three cases in group II and in one case in group HI.
During the observation period, improvement in kidney function was
observed in two cases in group II but deterioration in kidney function
was observed in one case in group I and in one other case in group III.
We conclude that in patients with schistosomal nephropathy, none of
the tried therapeutic regimens produce regression of the disease if given
to patients with established disease,
We have previously reported the existence of schistosomal
specific nephropathy in clinical settings and that this disease
may progress to end-stage renal failure [1, 21. The treatment of
schistosomal nephropathy is still unknown. The objective of
this work was to study the effect of three therapeutic modalities
on schistosomal nephropathy.
Patients with active Schistosoma mansoni infection with
renal involvement by specific lesions were selected for this
study. Activity of Schistosomal infection was documented by
the demonstration of living Schistosoma mansoni eggs in the
stool or in the rectal mucosal biopsy. Schistosomal specificity
of kidney lesion was considered when there was no other cause
to explain the kidney disease combined with the demonstration
of schistosomal circulating anodic antigen (CAA) and/or circu-
lating cathodic antigen (CCA).
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Methods
Clinical and laboratory evaluations
Patients with nephropathy and active Schistosoma mansoni
infection were subjected to evaluations which included thor-
ough history taking and clinical examination, evaluation of the
degree of edema, blood pressure, presence of concomitant
infection, 24-hour urinary protein, serum creatinine, creatinine
clearance, plasma albumin, plasma total proteins, serum cho-
lesterol and complement components C3 and C4, L.E. cells,
anti-DNA, C-reactive protein, anti-streptolysin-O titer, fasting
and post-prandial blood suger.
Kidney biopsy
Two cores of kidney tissue were obtained from the lower pole
of the right kidney by percutaneous needle approach.
1. One was fixed in 10% formalin and processed as paraffin
sections which were stained with hematoxylin and eosin,
periodic acid schiff, mathon trichrome, silver methenamine
and Congo red stains, and examined by light microscopy for
determination of the pathologic nature of kidney lesions.
2. The second core was immediately deep frozen (—70°C); for
immunofluorescent study.
Direct immunofluorescence. Kidney sections were stained
by fluorescein-labeled anti-human tgG, 1gM, IgA, C3, C4, Cq
and fibrinogen at dilutions of 1/8 to 1/10 and examined according
to the standard procedures.
Indirect immunofluorescence. Frozen sections were exam-
ined by using monoclonal anti-schistosomal CAA and monoclo-
nal anti-CCA in a working dilution (1:1000). FITC-labelled
anti-mouse IgG was used as a second layer in a working dilution
(1:10). These antibodies were prepared as described by Deelder
et al [3, 41. Sections from adult Schistosoma mansoni worm
fixed in Rossman's fixative were included as positive control,
and frozen kidney sections from non-schistosomal cases with
idiopathic nephrotic syndrome served as negative control.
Spec/icity studies. Cases positive for schistosomal antigens
by indirect immunofluorescent studies were further subjected to
specificity studies, these included the following:
(a) Absorption experiments. The non-labelled monoclonal
antibodies (anti-CAA and anti-CCA) with working dilution
1:1000 were incubated at 4°C overnight with adult worm sec-
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tions. Kidney sections were re-examined by indirect immuno-
fluorescence using the absorbed antisera as first layer and
FITC-labelled anti-mouse IgG as a second layer in a working
dilution of 1:10.
b) Tissue elusion study. Only positive cases with sufficient
kidney tissue as well as five control cases were subjected to this
study. Tissue elusion was performed as previously described [1,
2]. Eluates of schistosoma-positive and control cases were
tested against paraffin sections of adult Schistosoma mansoni
worm fixed in Rossmans fixative. An indirect immunofluores-
cence test was performed in which the eluate worked as a first
layer and FITC-labelled polyvalent anti-human immunoglobulin
as second layer.
Therapeutic protocols
Patients with schistosomal specific lesions were randomly
distributed among three groups. Group I cases were given
anti-schistosomal treatment (Oxamniquine and Praziquantel),
group II cases were given anti-schistosomal treatment and
prednisolone, and group III cases were given anti-schistosomal
treatment and cyclosporine. Oxamniquine was given in a total
oral dose of 40 to 60 mg/kg administered on three successive
days, and praziquantel was given as a single oral dose of 15
mg/kg.
Prednisolone was given in a dose of 60 mg/day orally for eight
weeks, then gradually withdrawn over 24 weeks.
Cyclosporine was given for 12 weeks orally in a dose of 5
mg/kg/day; this was given in two divided doses and readjusted
so as to have a whole blood trough level of 200 to 300 ng/ml as
measured by polyvalent RIA kits (Sandoz).
Follow-up
Patients were followed up every other week in the out-patient
clinic where they were examined clinically and subjected to
blood analysis for their serum creatinine, plasma total protein,
plasma albumin, serum cholesterol and urine analysis for pro-
teinuria.
Endpoint
End-point for this study was 12 months following initiation of
the treatment. At that time patients were evaluated clinically
and biochemically as well as by kidney biopsy.
Histopathologic re-evaluation
Patients were readmitted. Cure from Schistosoma mansoni
infection was assured by absence of living Schistosoma man-
soni ova in the rectal mucosal biopsy. Kidney biopsy was then
performed and was examined as previously described. When
microscopic examination by indirect immunofluorescence
showed a decrease or disappearance of the schistosomal-spe-
cific antigen(s) (CAA and/or CCA) deposits, tissue elution was
performed. Sections subjected to tissues elution were re-exam-
ined by indirect immunofluorescence using anti-CAA and anti-
CCA. Furthermore, eluates of these cases were tested for
presence of schistosomal antibodies by using adult worm cross-
sections fixed in Rossman's fixative.
Statistical analysis
The results of the laboratory data were expressed as mean
standard deviation. Statistical analysis was undertaken by
Table 1. Evaluation of patients subjected to the study
Group I II III
Number 8 10 8
Age 20.2 19.6 22.8
Sex
M 7 8 6
F 1 2 2
Presentation
Nephrotic syndrome 7 10 6
Non-nephrotic proteinuria 1 0 2
Hypertension 0 0 0
High serum creatinine 1 2 1
Histopathology
Mesangio capillary glomerulonephritis 2 4 2
Mesangial proliferative glomerulonephritis 2 3 3
Focal and segmental glomerulosclerosis 3 1 1
Membranous glomerulonephntis 1 1 1
No change 0 1 1
Table 2. Response to treatment
Group I II III
Remission of proteinuria
Complete 0 2 1
Partial 1 3 1
No 7 5 6
Serum creatinine
Increase 1 0 1
Stable 7 8 7
Decrease 0 2 0
Histopathologic
Progression 1 2 1
Stable 7 8 7
Regression 0 0 0
Drug toxicity 0 2 2
Student's paired t-test. Significance of differences was accepted
at P < 0.05.
Results
Twenty-six patients fulfilled the criteria for admission to the
study.
Table 1 shows the clinical, the laboratory and the histopatho-
logic criteria of these patients. Mesangial proliferative glomer-
ulonephritis, mesangiocapillary glomerulonephritis and focal
segmental glomerulosclerosis were the common lesions en-
countered in this group of patients. Most of the patients were
nephrotic, normotensive and with normal serum creatinine.
Table 2 shows the response to treatment in the three groups.
Following treatment, complete clinical and laboratory remis-
sion was documented in two cases in group II and in one case
in group III; the duration of remission was four to eight months.
Partial remission defined as reduction in the degree of 24
hour proteinuria was observed in one case in group I, in three
cases in group II and in one case in group III. The duration of
these remissions ranged from four to eight months also. There
was no response to treatment in seven cases in group I, in five
cases in group II and in six cases in group III. Cyclosporine was
stopped in one case due to acute nephrotoxicity.
Histopathologic re-evaluation showed no regression in le-
sions in any of the three groups, and progression of the kidney
disease was observed in one case in group I, in two cases in
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Fig. 1A. Kidney biopsy of a case from group II before treatment showing segmental hyaline thickening of the basement membrane with mild
increase in mesangial cells and interstitialfibrosis (H & E x 250). B. Biopsy from the same patient, after treatment showing advanced mesangial
hypercellularity and an increase in the interstitial fibrosis.
Fig. 2A. Kidney biopsy of a case from group III before treatment showing focal segmental glomeruloslerosis (PAS X 250). B. Biopsy from the
same patient but after treatment showing interstitial fibrosis and atrophic dilated tubules. (PAS x 250).
Table 3. Laboratory evaluation of patients with schistosomal specific nephropathy groups before and after treatment
I 11 III
Before AfterBefore After Before After
Serum creatinine 0.82 .20 0.85 0.32 0.99 0.45 0.95 0.48 0.68 0.22 0,54 0.18
Plasma total protein 5.8 0.8 5.7 0.7 5.0 0.44 5.8 0.88k 554 0.91 5.52 0.61
Plasma albumin 2.7 0.8 2.5 0.7 2.3 0.39 2.93 0,4a 2.62 0.75 2.6 0.7
Serum cholesterol 380 120 390.8 186 340.7 124.9 278.7 108.9 357 188 337 159
24 Hour proteinuria 3.9 2.1 3.99 2.2 4.47 2.2 3.92 3.47 2.92 1.6 3.56 2.42
a p < 0.01
group II and in one case in group III. This progression was
mainly in form of an increase in the interstitial fibrosis, tubular
atrophy and in the extent of the mesangial proliferation (Figs. 1,
2).
Table 3 shows the biochemical evaluations of the patients
before initiation of treatment and at the end point of the study.
There was no observed statistical difference in group I and III,
yet there was significant increase (P < 0.01) in the plasma
albumin and total protein in group II cases. In addition, there
was reduction in the 24 hour proteinuna, but this did not rank to
significance (P > 0.05).
In no case was there toxicity related to the intake of the
anti-schistosomal drugs. In those received prednisolone, one
developed osteoporosis and another suffered from steroid-
related diabetes and gastrointestinal hemorrhage. In those who
received cyclosporine, one suffered from nephrotoxicity and
another suffered from hepatotoxicity; these were completely
reversible on drug withdrawal.
— a - a
L 
-
-
 
fl,
 t. 
II S 
Sobh et a!: Schistosomal nephropathy 907
Discussion
Schistosomiasis is a helmenthic disease of man and animal. A
glomerulopathy related to Schistosoma mansoni infection has
been described [1, 2, 5, 6]. The presence of schistosomal
antigens together with immunoglobulins and complement in the
glomerular lesions associated with schistosomiasis has been
considered as good evidence of an immune complex mechanism
for schistosomal glomerulopathy [7, 8]. Furthermore, Hillyer
[9] suggested that DNA and DNA antibodies may play a role in
the pathogenesis of renal lesions in schistosomiasis. Thus,
schistosomal glomerulopathy resembles that of systemic lupus
erythematosus where pathogenesis is mediated by antibodies to
DNA. No treatment has been known for schistosomal nephrop-
athy until now. The objective of this work was to study the
effects of three therapeutic modalities on schistosomal nephrop-
athy. In all of the three groups, eradication of the parasite by
anti-schistosomal drugs was achieved. A combination of two
effective drugs was used [10—12]. Absence of living Schisto-
soma mansoni eggs in stool analysis and rectal mucosal biop-
sies performed 12 weeks after giving the drugs and at the end
point of the study confirmed the efficacy of anti-schistosomal
treatment and excluded the possibility of re-infection. It is
reported that parasitological methods which detect ova are
currently superior to serological or other indirect tests of
infection [13, 14]. In the second group prednisoline was given as
well and cyclosporine was given for those in group three. All
patients subjected to this study were of young age and all except
three were presenting with nephrotic syndrome. All patients
were normotensive, four cases showed mild to moderate eleva-
tion in serum creatinine. Mesangial proliferative glomerulone-
phritis and mesangiocapillary glomerulonephritis were the two
most common lesions encountered in these cases. Schistosomal
specificity of these kidney lesions was confirmed by absence of
other etiologic cause and the demonstration of schistosomal
specific antigens and antibodies deposited in the renal glomer-
uli.
Complete clinical and laboratory remissions were observed in
only three cases and partial remissions were observed in other
five, yet these remissions were of short duration: the mean
period was six months. During the observation period rise of
serum creatinine was noticed in one case in those given
anti-schistosomal treatment alone and in another case among
those given cyclosporine treatment. Nevertheless, improve-
ment in kidney function as judged by the drop in serum
creatinine was observed in two cases among those treated by
prednisolone. Histopathologic re-evaluation showed that in
most cases there were no remarkable changes and histopatho-
logic progression of the disease was observed in four cases.
There was no toxicity related to the intake of anti-schisto-
somal drugs, yet hepatotoxicity and nephrotoxicity were ob-
served in two cases in the cyclosporine treated group, and in
prednisolone treated group one patient suffered from steroid
related diabetes and severe upper gastrointestinal hemorrhage
secondary to gastric ulcer, and another patient suffered from
osteoporosis.
The prednisolone treated group showed better response than
those given anti-schistosomal treatment alone and those given
anti-schistosomal treatment plus cyclosponne. Nevertheless,
since the remissions observed were of short duration and there
was no concomitant histopathologic regression of the disease
and due to the significant drug related toxicity, we conclude that
none of the tried therapeutic regimens give satisfactory re-
sponse if administered in the same doses for similar durations to
patients who have an established disease state. Another thera-
peutic approach for treatment of this disease in its early and late
phases should be sought.
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